English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-α plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (e), the slope of the final phase ( X), that is, the second phase in biphasic decreases and the third phase in triphasic decreases, depends on the infected cell loss rate (δ). In standard models, X is approximately εδ when the viral clearance rate c&gt;&gt;δ, as has been previously estimated.Methods   The relationship among e, S, X and the baseline fraction of HCV-infected hepatocytes (π) was investigated in a model that included proliferation of hepatocytes.Results   We found that X was not proportional to e, but rather obeyed a complex relationship that could lead to dramatic increases in estimates of 8 as e increased. In particular, when ε 99%, δ∼λ regardless of π.Conclusions   Our results indicated that in patients undergoing therapy who achieved a 2 log 10  reduction in viral load (ε 99% should allow for a more accurate estimate of 8 in HCV RNA kinetic studies. This might be important when using viral kinetics to estimate the effect of the immune response on viral elimination and the attainment of sustained virological response.

Modelling Hepatitis C virus Kinetics: The Relationship between the Infected Cell Loss rate and the Final Slope of Viral Decay